Portfolio

  • Kantum Pharma Founder to Present Preclinical Data Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting

    November 4, 2019

    November 4, 2019 3:30pm Eastern Daylight Time CAMBRIDGE, MA (Newswire.com) - ​Kantum Pharma Inc., a biopharmaceutical company focused on developing therapies for the prevention and treatment of damaging inflammation triggered by innate immunity, announced today that the Company’s scientific founder, Dr. Sylvie Breton, will present her lab’s groundbreaking research characterizing a key pathway responsible for initiating renal inflammation and a therapeutic approach for preventing Acute Kidney Injury (AKI).   Title: The P2Y14 Receptor: Linking the Intercalated Cell to Immune

    Read More
  • CroíValve Secures €4M in Additional Funding to Initiate Clinical Trials

    September 12, 2019

    September 12, 2019 07:00 AM Eastern Daylight Time DUBLIN (BUSINESS WIRE)– €4 million in additional financing has been secured by CroíValve, a high potential start-up (HPSU) supported by Enterprise Ireland developing a treatment for tricuspid regurgitation (TR). This is an issue affecting over half-a-million people every year in the US and EU alone, for which there is currently no suitable solution. The financing includes €2.5 million from the European Union under their Horizon 2020 SME Instrument grant and €1.5 million from Broadview Ventures and current investors (HBAN MedTech and

    Read More
  • Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease

    August 14, 2019

    August 14, 2019 07:00 AM Eastern Daylight Time PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, and joined by New Leaf Venture Partners and Innogest Capital. Renovacor’s lead program is a recombinant adeno-associated virus (AAV)-based gene therapy for patients suffering from dilated card

    Read More
  • FineHeart makes Fierce Medtech’s 2018 List

    February 11, 2019

    February 11, 2019. FineHeart makes Fierce Medtech’s 2018 list of 15 exciting/innovative companies to watch. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today. Read more here

    Read More
  • Broadview Ventures 2018 Annual Report

    February 6, 2019

    Broadview Ventures 2018 Annual Report

    Read More
  • Vectorious Medical Technologies Announces World’s First In-Heart Microcomputer for Left Atrial Pressure Monitoring

    February 4, 2019

    Tel-Aviv, Israel (4 February, 2019) – Vectorious Medical Technologies, a medical device company enabling optimal management for heart failure patients, today announced the initiation of the VECTOR-HF First-in-Human (FIH) clinical trial, and the successful first ‘in-human’ implantation of the V-LAPTM monitoring device. Link to Press Release  

    Read More
  • Remedy Publication: Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial

    December 4, 2018

    Link to publication

    Read More
  • ZZ Biotech Publication: Final Results of the RHAPSODY Trial

    November 9, 2018

    Link to publication

    Read More
  • Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

    November 5, 2018

    COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound in cardioversion, AP30663. The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.  Link to Press Release

    Read More
  • AtaCor Medical Raises $8.8M to Develop Substernal Cardiac Pacing System

    September 18, 2018

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing system. Link to Press Release

    Read More